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Richard Jones,1 Jane Lebkowski,2 Ian McNiece3Stem cells offer the potential of new therapies for previously untreatable diseases. This session focuses on
different aspects of stem cells from embryonic stem cells to adult stem cells and the biology and therapeutic
impact of cancer stem cells.
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Stem cell research offers opportunities for develop-
ing new medical therapies for debilitating diseases and
a newway to explore fundamental questions of biology.
Stem cells (SCs) are defined as cells that can self-renew
and differentiate into mature functional cells. If we can
determine the mechanisms that control the prolifera-
tion and differentiation of SCs, it may be possible to
engineer cells for therapeutic benefit. Therefore, it is
important to explore all sources of SCs: embryonic
(ES), adult, and induced pluripotent stem cells (iPS).
Each population offers different advantages and disad-
vantages. Some of these properties will be presented in
the presentations that follow, but it is unlikely that
a single SC source will be applicable for all diseases.
In contrast, each disease presents its own set of prob-
lems and complexities, and subsets of patients within
diseases present differing challenges. Most likely pa-
tient-specific cellular products (eg, products generated
from iPS cells) will be limited because of cost and time
for manufacture. Allogeneic cellular products will be
limited by HLA barriers and potential rejection or
graft-versus-host disease (GVHD). A number of clini-
cal trials are evaluating the use of autologous cellular
products and other complexities will limit access to
these products because of factors such as time for pro-
duction. Therefore, carefully designed clinical trials
are needed to evaluate the potential of cellular products
from various SC sources to define the limitations in
production, delivery, and clinical benefit.1Johns Hopkins University, Baltimore, Maryland; 2Geron
, Menlo Park, California; and 3University of Miami,
i, Florida.
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6/j.bbmt.2009.10.035This session on SCs consists of 3 presentations that
will focus on the biology and translational aspects of
human embryonic stem cells (Jane Lebkowski), cancer
stem cells (Richard Jones), and adult stem cells (Ian
McNiece).HUMAN EMBRYONIC STEM CELLS (hESCs)
JANE LEBKOWSKI
Many investigators have been evaluating the
potential of hESCs to generate cells for clinical appli-
cations. Embryonic SC-derived neural cells have been
used to treat nervous system disorders in animal
models. In the case of spinal cord injuries, neural cells
derived from animal ESCs and injected into the spinal
cord injury site produced significant recovery of the
animal’s ability to move and bear weight. To apply
those observations to humans, Geron has derived
oligodendrocyte progenitor cells (GRNOPC1) from
hESCs. Oligodendrocytes are naturally occurring cells
in the nervous system that have several functions.
Oligodendrocytes produce myelin (insulating layers
of cell membrane), which wraps around the axons of
neurons to enable them to conduct electrical impulses.
Myelin enables efficient conduction of nerve impulses
in the same manner as insulation prevents short
circuits in an electrical wire. Without myelin, many
of the nerves in the brain and spinal cord cannot func-
tion properly. Oligodendrocytes also produce neuro-
trophic factors (biologics that enhance neuronal
survival and function) to support the maintenance of
nerve cells. Oligodendrocytes are lost in spinal cord
injury, resulting in myelin and neuronal loss that cause
paralysis in many patients with spinal cord injuries.
In our collaboration with researchers at the Uni-
versity of California, Irvine, we have shown in animal
models that GRNOPC1 can improve functional loco-
motive behavior after implantation in the injury site
7 days after injury. Histologic analysis also provided
evidence for the engraftment and function of theseS115
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the Journal of Neuroscience [1]. In additional studies,
the lesion site of animals 9months after injury and sub-
sequent injection of GRNOPC1 was observed to be
essentially filled with GRNOPC1 and myelinated rat
axons crossing the lesion. These animal observations
serve as the rationale for the use of GRNOPC1 in
treating spinal cord injuries in humans.
We have developed a functional cryopreserved for-
mulation of GRNOPC1 for use in clinical trials, and
have initiated current good manufacturing practices
(cGMP) production of GRNOPC1 in our qualified
manufacturing facilities.
After completion of extensive animal toxicology
testing, which included 24 separate studies in rats and
mice that required more than 5 billion GRNOPC1
cells, we filed a 21,000 page investigational new drug
(IND) with the U.S. Food and Drug Administration
(FDA) containing data from the animal and in vitro
testing of the cells to ensure the highest possible
degree of safety of the product before initiating human
clinical trials.
In January 2009, we received clearance from the
FDA to begin the world’s first human clinical trial of
an ESC-based therapy usingGRNOPC1 for acute spi-
nal cord injury. The IND is currently on clinical hold
by the FDA pending the agency’s review of new non-
clinical animal study data submitted by the company.CANCER STEM CELLS
RICHARD JONES
Background
Only a minority of cells from most hematologic
malignancies and solid tumors are clonogenic in vitro
and in vivo. This low clonogenic potential could repre-
sent proliferative capacity exclusively restricted to
a small subset of cancer cells, or alternatively, all the
cells within a cancer retaining the capacity to prolifer-
ate but only at a low rate.Which of these 2 possibilities
explains the low clonogenicity of most cancers has
been debated for years. Fialkow and his colleagues
[2] first suggested that chronic myelogenous leukemia
(CML) arose from rare transformed hematopoietic
stem cells (HSCs) nearly 40 years ago, when they
showed that both granulocytes and red blood cells
from CML patients were derived from a common
cell. The first modern use of the term cancer or tumor
SCs is attributed to Park et al. [3], who found that only
aminority ofmousemultiplemyeloma cells were capa-
ble of clonogenic growth. The SC origin of CML was
confirmedmore than 15 years ago when several groups
utilized phenotypic characteristics of HSC to identify
and isolate CML cells capable of expansion ex vivo
[4]. Dick and colleagues [5,6] extended these observa-
tions, showing that phenotypic primitive HSCspurified from patients with both acute myelogenous
leukemia (AML) and CML would generate leukemia
in vivo when injected into nonobese diabetes/severe
combined immunodeficiency (NOD/SCID) mice.
Such cells have more recently been described in
many other malignancies [7,8]. A recent consensus
conference defined Cancer Stem Cells (CSC) cardiac
stem cells (CSCs) as tumor cells possessing the capac-
ity for self-renewal and generating the cells that com-
prise the tumor bulk [8]. Although CSCs have been
hypothesized to arise from transformed normal cells
with SC properties, it is very possible that the transfor-
mation process itself may be able to induce self-
renewal capacity. Hence, these cells have also been
designated ‘‘tumor-initiating’’ or ‘‘tumorigenic’’ cells,
although the most commonly used label remains
CSCs [8]. The current gold standard for identification
of CSCs requires that they possess the ability to engraft
immunodeficient mice [5,9]. However, this is an
artificial culture system that could either under- or
overestimate the true frequency of CSCs.Clinical Relevance
Therapeutic advances over the past 3 decades now
allow most cancer patients to achieve major clinical
responses. Although clinical responses can clearly
decrease side effects and improve quality of life, most
cancer patients still eventually relapse and die of their
disease. Putative CSCs have been reported to be rela-
tively resistant to standard anticancer therapies
[10-12], at least in part by co-opting normal SCs’
intrinsic defense mechanisms such as quiescence, ef-
flux pumps, and detoxifying enzymes [11]. The CSC
concept proposes that initial responses represent ther-
apeutic effectiveness against the cancer cells making up
the bulk of the tumor, whereas CSCs are responsible
for most relapses, and must be eliminated to realize
cures [7,13]. However, currently there are no definitive
data that CSCs from any malignancy are, in fact,
responsible for disease relapse or resistance. Thus,
the data on CSCs remain largely laboratory curiosities,
leading many investigators to question the biologic
and clinical relevance of these cells [14].
However, emerging data suggest for the first time
a clinical relevance for CSCs.Multiplemyeloma (MM)
has long been considered a malignancy of plasma cells,
because they form the bulk of the tumor. However,
several groups have recently shown that the myeloma
plasma cells actually arise from a minute population
of less differentiated CSCs, which resemble memory
B cells and have the ability to self-renew, differentiate,
and generate the disease in vitro [15,16] and in NOD/
SCID mice [11]. A report using rituximab to target
myeloma CSCs (myeloma plasma cells usually do
not express CD20) found a strong and significant asso-
ciation between myeloma CSC numbers in patients
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(PFS) [17]. Moreover, rituximab could be detected
on the surface of circulating myeloma CSCs from pa-
tients who progressed, suggesting that the therapeutic
concept was valid, but that rituximab was unable to kill
the myeloma CSCs. Residual breast tumor cell popu-
lations persisting after conventional treatment have re-
cently been shown to be enriched for phenotypic
breast CSCs [18].
Summary
Initial responses in cancer represent therapeutic
effectiveness against the cancer cells making up the
bulk of the tumor; emerging data suggest that resistant
CSCs are often responsible for relapse. Because many
currently active treatments have been developed to tar-
get the cancer cell bulk, they may have little activity
against biologically distinct CSCs. Moreover, tradi-
tional response criteria measure tumor bulk and may
not reflect changes populations of rare CSCs [7].
Standard response parameters may not only poten-
tially overestimate the effect of therapy on the minute
population of stem cells, but may also underestimate it.
Therapy selectively directed at CSCs will not im-
mediately eliminate the differentiated tumor cells;
such therapy, therefore, might be prematurely aban-
doned if clinical activity is judged solely by standard
response criteria that reflect the effects of treatment
on the bulk of the cancer. Thus, it is likely that im-
proving the results of cancer therapy requires identifi-
cation and better understanding the biology of CSCs,
as well as reexamining both our preclinical and clinical
drug development paradigms to include the CSC
concept.ADULT STEM CELLS
IAN MCNIECE
The maintenance of homeostasis requires con-
stant cell production to replace dead and damaged
cells. Adult SCs reside in the tissues and differentiate
to functional mature cells. The control of prolifera-
tion and differentiation of a number of types of SCs
occurs in the microenvironmental niche or the SC
niche. HSCs have been studied in detail and shown
to reside in the BM in association with stromal cells
that make up the hematopoietic microenvironment
[19]. The stroma consists of several cell populations
including mesenchymal stromal cells (MSCs), fibro-
blasts, and adventicular reticulocytes [20]. HSCs exist
in a quiescent state in close relationship with the stro-
mal cells in the BM. These stromal cells produce
a number of cytokines and growth factors that are
either secreted or expressed as membrane bound pro-
teins, and these cytokines and growth factors control
the differentiation and proliferation of the HSCs. Invitro, MSCs have been shown to support the prolifer-
ation and differentiation of HSCs, generating com-
mitted hematopoietic progenitor cells over a 6-week
period [21]. If the microenvironment is compro-
mised, such as in patients who receive multiple
rounds of high-dose chemotherapy regimens, normal
homeostasis is disrupted and deficiencies in blood
cells occur.Stromal Cells in Cardiac Tissue
The extracellular matrix (ECM) of cardiac tissue,
which is composed of a number of cells including
cardiac fibroblasts, mesenchymal cells, fibronectin,
and other matrix proteins [22-24], provides elasticity
and mechanical strength. We have isolated several
stromal cell populations from human fetal heart
that are positive for CD105, CD90, and CD73, but
negative for CD34 and CD45, which is consistent
with the phenotype of BM-derived MSCs. Given
the homeostatic role of MSCs in regulation of
HSCs, it is highly likely that cardiac stromal cells
play a regulatory role in the control of proliferation
and differentiation of CSCs and cardiac progenitor
cells (CarSC and CPC) (CPCs). This role could be
performed through the secretion of a range of growth
factors and cytokines.
Myocardial infarction (MI) results in ischemic dam-
age, which results in cell death of not only cardiomyo-
cytes, but also fibroblasts and most likely stromal
cells. Even with migration of viable CarSCs and
CPCs to the ischemic tissue, the lack of stromal ele-
ments would result in the failure of the CarSCs and
CPCs to proliferate and differentiate, hence failure of
remodeling. Along with the recent identification of car-
diac SCs in heart tissue, this offers insights into the bi-
ology of ischemic heart damage. Patients with an MI
have ischemic tissue that fails to regenerate, andwepro-
pose that this is in part because of destruction of cardiac
stromal cells.
MSCderived fromBMcells have been evaluated for
cardiac regenerative therapy [25] and offer advantages
over other sources of stem cells because of their avail-
ability, immunologic properties, and record of safety
and efficacy. Studies of MSC engraftment in rodent
and swine models of MI demonstrate: (1) functional
benefit in post-MI recovery with administration, (2) ev-
idence of neoangiogenesis at the site of the infarct, (3)
decrease in collagen deposition in the region of the
scar, and (4) some evidence of cells expressing con-
tractile and sarcomeric proteins, but lacking true
sarcomeric functional organization. Administration of
autologous or allogeneic humanMSCs to cardiovascu-
lar patients has been performed in several clinical stud-
ies to date, all in the post-MI setting. The MSCs have
been administered via the intracoronary (i.c.) route,
via peripheral intravenous (i.v.) injection or direct
S118 Biol Blood Marrow Transplant 16:S115-S118, 2010R. Jones et al.injection into the cardiac tissue with surgery. Prelimi-
nary data suggest improved cardiac function in patients
receiving MSC; however, these results need to be stud-
ied in larger randomized trials [26].
Based upon data from animal studies and prelimi-
nary clinical data we propose that optimal repair of
ischemic tissue requires regeneration of both stromal
elements and cardiomyocytes. Delivery of MSC to
the ischemic tissue can regenerate the stroma and de-
livery of CSCs/CPCs can regenerate cardiomyocytes.
We further propose that the combination cellular
therapy is necessary for optimal repair as delivery of
CSCs/CPCs will result in minimal repair because of
the lack of a niche and the absence of appropriate
growth factors and cytokines for these cells to prolifer-
ate and differentiate.ACKNOWLEDGMENTS
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